Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.
Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.
复制标题
DOI：
10.1586/14760584.2.2.295
复制
发表时间：
2003-04-01
影响因子：
6.2
通讯作者：
Moser, Christian
中科院分区：
文献类型：
--
作者：
Zurbriggen, Rinaldo;Metcalfe, Ian C;Moser, Christian
目前使用的常规流感疫苗是肠胃外施用的，并且通常通过诱导高滴度的血清病毒中和抗体来赋予针对全身性疾病的良好保护。胃肠外疫苗是次优的，因为它们无法诱导可能预防病毒感染早期阶段的局部粘膜反应。因此，疫苗的鼻内给药可提供胃肠外途径的可行替代方案。实际上，当与适当的粘膜佐剂（例如，细菌毒素），导致强烈的局部和全身免疫应答。本文综述了大肠杆菌不耐热毒素作为鼻内注射流感疫苗粘膜佐剂的非临床安全性评价。
Conventional influenza vaccines currently in use are administered parenterally and generally confer good protection against systemic disease through the induction of high titers of serum virus-neutralizing antibodies. Parenteral vaccines are suboptimal in that they fail to induce a local mucosal response that may prevent the early stages of virus infection. Thus, the intranasal administration of a vaccine may provide a viable alternative to the parenteral route. Indeed, intranasal administration of vaccine antigens when formulated with an appropriate mucosal adjuvant (e.g., bacterial toxins), results in a vigorous local and systemic immune response. This review discusses the nonclinical safety evaluation of Escherichia coli heat-labile toxin as a mucosal adjuvant for an intranasally administered influenza vaccine.